Madrona Ventures led a $20m investment in Archon Biosciences.

Madrona Ventures, a venture capital firm, led a $20m investment in Archon Biosciences, a biotechnology company that designed Antibody Cages (AbCs) to unlock powerful therapeutic targets beyond the reach of existing modalities, with participation from DUMAC, Sahsen Ventures, WRF Capital, Pack Ventures, Alexandria Venture Investments and Cornucopian Capital. “There are many high-profile cases where we understand not only a target’s biology but also why past attempts to drug the target have failed in the clinic. These key disease levers are at our fingertips, but we lack the tools to safely and effectively engage them. Our transformational Antibody Cage technology is designed to drug many of these challenging targets underlying diseases of paramount urgency and create better treatment options for patients. With the support of our investors, we have developed a proprietary protein design platform coupled with rapid in-house manufacturing and testing to revolutionize how biologics are developed,” James Lazarovits, Archon Biosciences, co-founder and chief executive officer.